title: Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Plumb
authors.forename: Andreas
authors.initials: A
authors.lastname: Clemens
authors.forename: Brigitta U
authors.initials: BU
authors.lastname: Monz
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D000991:Antithrombins / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D019644:Arthroplasty, Replacement, Hip; D019645:Arthroplasty, Replacement, Knee; D001562:Benzimidazoles / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D000069604:Dabigatran; D017984:Enoxaparin / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D000077425:Fondaparinux; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D018803:Models, Economic; D009025:Morpholines / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D011134:Polysaccharides / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D011183:Postoperative Complications / Q000191:economics* / Q000209:etiology / Q000517:prevention & control*; D011725:Pyridines / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000191:economics* / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D017984:Enoxaparin; D006495:Heparin, Low-Molecular-Weight; D009025:Morpholines; D011134:Polysaccharides; D011725:Pyridines; D013876:Thiophenes; D000069552:Rivaroxaban; D000069604:Dabigatran; D000077425:Fondaparinux
references.citation: N Engl J Med. 2008 Jun 26;358(26):2765-75
references.pmid: 18579811
references.citation: Expert Opin Pharmacother. 2009 Aug;10(11):1769-81
references.pmid: 19548861
references.citation: N Engl J Med. 2008 Jun 26;358(26):2776-86
references.pmid: 18579812
references.citation: Lancet. 2008 Jul 5;372(9632):31-9
references.pmid: 18582928
references.citation: Lancet. 2007 Sep 15;370(9591):949-56
references.pmid: 17869635
references.citation: Curr Med Res Opin. 2008 Oct;24(10):2993-3006
references.pmid: 18814825
references.citation: Ann Surg. 2009 Aug;250(2):219-28
references.pmid: 19638915
references.citation: Curr Vasc Pharmacol. 2009 Jul;7(3):309-29
references.pmid: 19601856
references.citation: J Thromb Haemost. 2007 Nov;5(11):2178-85
references.pmid: 17764540
references.citation: Pharmacoeconomics. 2009;27(10):829-46
references.pmid: 19803538
references.citation: Clin Appl Thromb Hemost. 2009 Jul-Aug;15(4):377-88
references.pmid: 19608549
references.citation: Thromb Haemost. 2010 Feb;103(2):360-71
references.pmid: 20024501
references.citation: Clin Ther. 2009 Jan;31(1):194-212
references.pmid: 19243718
references.citation: Pharmacoeconomics. 2010;28(7):521-38
references.pmid: 20550220